Placebo News and Research RSS Feed - Placebo News and Research

EPO administered to preterm infants linked with reduced risk of brain injury

EPO administered to preterm infants linked with reduced risk of brain injury

High-dose erythropoietin (EPO; a hormone) administered within 42 hours of birth to preterm infants was associated with a reduced risk of brain injury, as indicated by magnetic resonance imaging, according to a study in the August 27 issue of JAMA. [More]
Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting. [More]
Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis. [More]
Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite. [More]
NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm signs definitive investment agreements for $16 million financing round

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that it has signed definitive investment agreements for a $16 million financing round led by certain of its existing investors with the participation of new investors, including The Elias Group. [More]
Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Patients with mild to moderate Alzheimer's disease currently have no treatment options to slow brain cell deterioration. Researchers at Houston Methodist's Nantz National Alzheimer Center are studying an investigational drug that proposes to do just that. [More]
Studies support clinical use of antidepressants for treatment of postoperative pain

Studies support clinical use of antidepressants for treatment of postoperative pain

Antidepressants are known to provide effective pain relief for various chronic pain conditions; however, the jury is still out on their use in treating the millions of patients who suffer from acute or chronic pain following surgery. [More]

Perampanel does not offer added benefit for patients with Epilepsy

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). [More]
Penn researchers analyze clinical practice guidelines

Penn researchers analyze clinical practice guidelines

The common thought in the medical community is that the randomized, controlled trial is the gold standard in medical research. [More]
University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

University of Kansas researcher earns grant to study role of dietary supplement in muscle growth

A University of Kansas professor has been chosen to take part in a grant project that will test the role of a dietary supplement in muscle growth for everyone from athletes to the elderly and has also been named educator of the year by the granting agency. [More]
Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints. [More]
Neo40 nitric oxide supplement helps promote normal blood pressure

Neo40 nitric oxide supplement helps promote normal blood pressure

Nitric oxide supplementation using a Neo40 lozenge significantly helps promote normal blood pressure, as indicated by a 30-day, blinded, placebo-controlled clinical study, conducted at the California Medical Institute by renowned cardiology researcher Dr. Ernst Schwarz. [More]
Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

Healthy men participating in Prostate Cancer Prevention Trial are most likely to undergo biopsy

Healthy men participating in the Prostate Cancer Prevention Trial who actively participate in all steps of the clinical trial are most likely to undergo a biopsy, according to a study published in Cancer Epidemiology, Biomarkers and Prevention - a journal of the American Association for Cancer Research. [More]
Umeclidinium/vilanterol outperforms monotherapies in COPD

Umeclidinium/vilanterol outperforms monotherapies in COPD

A combination of umeclidinium and vilanterol is more effective than each drug as monotherapy for the treatment of chronic obstructive pulmonary disease, research indicates. [More]
Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Phase 2 study: Rigel's R348 fails to meet endpoints in patients with dry eye disease

Rigel Pharmaceuticals, Inc. today announced that R348, its ophthalmic JAK/SYK inhibitor, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study in patients with dry eye disease. [More]
Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa obtains $10 million senior credit facility to support NDA submission for Ostora tablet

Tarsa Therapeutics, Inc. today announced that it has secured a $10 million senior credit facility from Oxford Finance LLC and Square 1 Bank. The company intends to use the proceeds to support its plans to file a New Drug Application (NDA) with the U.S. Food and Drug Administration for its Ostora tablet for the treatment of postmenopausal osteoporosis, currently targeted for early 2015. [More]
Study: Effects of testosterone on brain's response to threat cues in healthy men

Study: Effects of testosterone on brain's response to threat cues in healthy men

A new study in Biological Psychiatry reports on a neural circuit for male aggression. Testosterone, a steroid hormone, is well known to contribute to aggressive behavior in males, but the neural circuits through which testosterone exerts these effects have not been clear. [More]
Osteoporosis drugs may not protect women from breast cancer

Osteoporosis drugs may not protect women from breast cancer

Osteoporosis drugs known as bisphosphonates may not protect women from breast cancer as had been thought, according to a new study led by researchers at UC San Francisco (UCSF). [More]
BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies total revenue for second quarter decreases by 19%

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® (collagenase clostridium histolyticum or CCH) in the U.S. and XIAPEX® in the EU, today announced its financial results for the second quarter ended June 30, 2014 and provided a corporate update. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]